MIRA INFORM REPORT

Report Date :

21.01.2011

IDENTIFICATION DETAILS

Name :	NAWAN LABORATORIES (PRIVATE) LIMITED

Registered Office :	136 - 138, Sector 15, Korangi Industrial Area, Karachi,

Country :	Pakistan

Year of Establishment :	1995

Com. Reg. No.:	0034937

Legal Form :	Private Limited Company

Line of Business :	Manufacture & Marketing of Pharmaceutical Products

RATING & COMMENTS

MIRA’s Rating :

RATING		STATUS	PROPOSED CREDIT LINE
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory

Status :	Satisfactory

Payment Behaviour :	No Complaints

Litigation :	Clear

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List – June 30, 2010

Country Name

Previous Rating

(01.04.2010)

Current Rating

(30.06.2010)

Pakistan

Risk Category	ECGC Classification
Insignificant	A1
Low	A2
Moderate	B1
High	B2
Very High	C1
Restricted	C2
Off-credit	D

Business Name

NAWAN LABORATORIES (PRIVATE) LIMITED

Full Address

Registered Address & Factory

136 - 138, Sector 15, Korangi Industrial Area, Karachi, Pakistan

Tel #	92 (21) 35065835 - 37 (3 Lines)
Fax #	92 (21) 35061936
Email	nawanlabs@cyber.net.pk

Short Description Of Business

Nature of Business	Manufacture & Marketing of Pharmaceutical Products
Year Established	1995
Registration #	0034937

Branches

In Lahore at present

Auditors

Mehmood Idrees Qamar & Co.

(Chartered Accountants)

103-104, Amber Estate, Shahrah-e-Faisal, Karachi, Pakistan

Legal Status

Subject Company was established as a Private Limited Company in 1995

Authorized Capital	Rs. 10,000,000/- divided into 100,000 shares of Rs. 100/- each
Issued & Paid up Capital	Rs. 10,000,000/- divided into 100,000 shares of Rs. 100/- each

Details of Chief Executive/ Directors

Names

Nationality

Address

Occupation

Designation

Mr. Naseer Ahmed Awan

Mr. Talat Naseer Awan

Mr. Ehsan Naseer Awan

Pakistani

64 Khayaban-e-Janbaz, Phase V, D.H.A., Karachi

Business

Chief Executive

Director

Shareholders

Names

No. of Shares

Mr. Naseer Ahmed Awan

Mr. Talat Naseer Awan

Mr. Ehsan Naseer Awan

80,000

10,000

Associates

A. Subsidiary

None

B. Associated Companies

(1) Nawan Trading Corporation, Pakistan.

Products / Services

Manufacture & marketing of Pharmaceutical Products by its brand name including AMLOWAN, ASPIWAN, AZIROMYCIN, CEFAWAN, CEFORIN, DICLOWAN, FAMOWAN, LEXIWAN, LOMIVAC, LORESTIN, NAFRADIN, NAMOXIL, NAWAZIN, NAWAZOLE, OLTRIX, VISCODIN

Number of Employees

150

Trade Suppliers (Foreign)

(1) HEBEI HUARI PHARMACEUTICAL CO. LTD, CHINA.

(2) ZHUHAI UNITED LABORATORIES CO., LTD, CHINA.

Annual Production Volume

The capacity and production of the company’s plant is indeterminable as it involves varying processes of manufacture.

Annual Sales Volume

Year	In Pak Rupees
2009	150,000,000/- (Estimated)

Distributors Network

Mainly exist at all major cities of Pakistan

Bankers

(1) Bank Alhabib Limited, Pakistan.

(2) Habib Bank Limited, Pakistan.

(3) Soneri Bank Limited, Pakistan.

Memberships

· Pakistan Pharmaceutical Manufacturers Association.(PPMA)

· Korangi Association of Trade & Industry.(KATI)

Foreign Exchange Rates

Currency	Unit	Pakistani Rupee
US Dollar	1	Rs. 85.90
UK Pound	1	Rs. 135.83
Euro	1	Rs. 115.36

Comments

Subject Company was established in 1995 and is engaged in manufacture & marketing of Pharmaceutical Products. Overall reputation is satisfactory. Trade relations are reported as fair. The Company can be considered for normal business dealings at usual trade terms & conditions.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	Rs.45.58
UK Pound	1	Rs.72.73
Euro	1	Rs.61.45

RATING EXPLANATIONS

RATING		STATUS	PROPOSED CREDIT LINE
>86	Aaa	Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums	Unlimited
71-85	Aa	Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums	Large
56-70	A	Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums	Fairly Large
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory
26-40	B	Capability to overcome financial difficulties seems comparatively below average.	Small
11-25	Ca	Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity	Limited with full security
<10	C	Absolute credit risk exists. Caution needed to be exercised	Credit not recommended
--	NB	New Business	--

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

Financial condition (40%) Ownership background (20%) Payment record (10%)

Credit history (10%) Market trend (10%) Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.